CML-CAB 2017 III
4th CML-CAB: Munich, Germany, 18-19 November 2017
On 18-19 November 2017, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, has hosted its fourth meeting to discuss issues of major concern to the CML community.
CML-CAB Members attending the 4th CML-CAB as patient experts:
- Jan Geissler, Germany (co-chair)
- Giora Sharf, Israel (co-chair)
- Jana Pelouchova, Czech Republic
- Mercedes Arteaga, Argentina (representing Latin America)
- Bahija Gouimi, Morocco (representing Africa and the Middle East)
- Rita Christensen, Denmark (representing Western Europe)
- Pat Garcia-Gonzalez - The Max Foundation USA (representing Latin America)
- Rod Padua, Philippines (representing East Asia and Pacific)
- Felice Bombaci, Italy (Western Europe)
- Ferdinand Micho, Kenya (Africa)
- Silvia Castillo De Armas, Guatemala (Latin America)
- Šarūnas Narbutas, Lithuania (Eastern Europe)
- Lisa Machado, Canada (North America)
- Cornelia Borowczak, Germany
Plus, the CML Advocates Network team Lidija Pecova and Celia Marín.
CML-CAB with Incyte & Takeda, 18th November 2017, 13:00-17:00
The following topics were discussed during the CML-CAB:
- Clinical Update on Ponatinib
- Discussion of The Lifecycle Plan for Ponatinib
- Access Issues
- Involvement of the CML Community in Research & Development (R&D)
- Dialogue and Next Steps
Non-confidential minutes of the meeting will be available to CML Advocates Network members soon.
CML-CAB with Novartis, 19th November, 08:00-16:00
The following topics were discussed during the CML-CAB:
- Clinical Development of ABL001 and Nilotinib
- Collaboration Between Novartis and CML Community in CML Drug Development
- Therapy-Free Remission
- Follow-up Actions and Next Steps
Non-confidential minutes of the meeting will be available to CML Advocates Network members soon.